cefaclor

Trade name: ceclor

Small moleculeapproved

Approved

Apr 4, 1979

Cefaclor is a semisynthetic cephalosporin antibiotic for oral administration. As with other cephalosporins, the bactericidal action of Cefaclor results from inhibition of cell-wall synthesis. Cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae, staphylococci, and Streptococcus pyogenes; Lower respiratory tract infections, including pneumonia, caused by Streptococcus pneumoniae, Haemophilus influenzae, and Streptococcus pyogenes; Pharyngitis and Tonsillitis, caused by Streptococcus pyogenes; Urinary tract infections, including pyelonephritis and cystitis, caused by Escherichia coli, Proteus mirabilis, Klebsiella spp., and coagulase-negative staphylococci; Skin and skin structure infections caused by Staphylococcus aureus and Streptococcus pyogenes. Adverse effects considered to be related to therapy with cefaclor are: Hypersensitivity reactions, Rarely, reversible hyperactivity, agitation, nervousness, insomnia, confusion, hypertonia, dizziness, hallucinations, somnolence and diarrhea. Patients receiving Cefaclor may show a false-positive reaction for glucose in the urine with tests that use Benedict's and Fehling's solutions and also with Clinitest® tablets. There have been reports of increased anticoagulant effect when Cefaclor and oral anticoagulants were administered concomitantly. — NCATS

Clinical trial activity

1 trials · 1 clinical orgs · 12 marketing orgs

Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
1

Earliest trial started Jun 1, 2022 (NCT05398679)

Timeline

1970s

  1. Apr 4, 1979

    Eli Lilly — Earliest FDA Approval

  2. Apr 4, 1979

    Eli Lilly — NDA Organization

  3. Apr 23, 1979

    facta — Marketing Organization

  4. Jul 28, 1979

    Ceph Intl — Marketing Organization

1990s

  1. Apr 27, 1995

    DAVA Pharmaceuticals — Marketing Organization

  2. Apr 27, 1995

    Teva — Marketing Organization

  3. May 23, 1996

    Watson Pharmaceuticals — Marketing Organization

  4. May 23, 1996

    Heritage Pharma — Marketing Organization

  5. May 23, 1996

    Chartwell Pharmaceuticals — Marketing Organization

  6. Aug 28, 1997

    Ranbaxy — Marketing Organization

2000s

  1. Jan 5, 2001

    Genelabs Technologies — Marketing Organization

  2. Jan 22, 2004

    Yung Shin Pharm. Ind. Co., Ltd. — Marketing Organization

  3. Apr 3, 2007

    Hikma — Marketing Organization

Indications

Mechanism of action

Approval history

  • approvedApr 4, 1979

Chemistry & pharmacology

Loading structure…

SMILES

N[C@@H](C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(Cl)CS[C@H]12)c1ccccc1
Mol. weight
367.81 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Prescription Only

Oral

Yes

Parenteral

No

Topical

No

Sources

Also known as

  • 3-chloro-7-d-(2-phenylglycinamido)-3-cephem-4-carboxylic acid
  • 3-chloro-7-d-(2-phenylglycinamido)-3-cephem-4-carboxylic acid
  • alfacet
  • bacticlor mr
  • ccl
  • ccl
  • ceclor
  • ceclor
  • ceclor
  • ceclor
  • ceclor cd
  • ceclor cd
  • cefaclor
  • cefaclor
  • cefaclor
  • cefaclor
  • cefaclor
  • cefaclor
  • cefaclor
  • cefaclor
  • cefaclor
  • cefaclor
  • cefaclor anhydrous
  • cefaclor anhydrous
  • cefaclor hydrate
  • cefaclor hydrate
  • cefaclor hydrate
  • cefacloro
  • cefacloro
  • cefaclorum
  • cefaclorum
  • céfeaclor
  • céfeaclor
  • cephaclor
  • cephaclor
  • cephaclor
  • compound 99638
  • compound 99638
  • distaclor
  • distaclor
  • distaclor
  • distaclor mr
  • keftid
  • losefar
  • raniclor
  • raniclor

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05398679Phase 4Jun 1, 2022University of Barcelona
Showing 1 of 1 trials
Page 1 / 1

Organizations

Research & Development (1)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
University of BarcelonaAcademic/Hospital1112022
1 organizations
Page 1 / 1

Marketing (14)

OrganizationOrg typeRelationshipDate
Ceph IntlFor profitMKTGJul 28, 1979
Chartwell PharmaceuticalsFor profitMKTGMay 23, 1996
DAVA PharmaceuticalsFor profitMKTGApr 27, 1995
Eli LillyFor profitNDAApr 4, 1979
Genelabs TechnologiesFor profitMKTGJan 5, 2001
Heritage PharmaFor profitMKTGMay 23, 1996
HikmaFor profitMKTGApr 3, 2007
RanbaxyFor profitMKTGAug 28, 1997
RanbaxyFor profitSYNDec 22, 2003
TevaFor profitMKTGApr 27, 1995
TevaFor profitSYNJun 24, 1996
Watson PharmaceuticalsFor profitMKTGMay 23, 1996
Yung Shin Pharm. Ind. Co., Ltd.For profitMKTGJan 22, 2004
factaFor profitMKTGApr 23, 1979